Dare Bioscience Q2 Loss Narrows, First Commercial Product Launches
DARE sits 45% above its 52-week low of $1.13 on elevated volume (3.7× avg).
Summary
Dare Bioscience reported Q2 revenue of $0.2M, up from the prior year, driven by R&D services revenue from Gates Foundation agreements. Net loss narrowed as R&D expenses declined, helped by reduced Ovaprene Phase 3 costs. The company launched Flora Sync LF5, its first directly commercialized product, in July and expects to begin recording revenue from DARE to PLAY Sildenafil Cream in Q3 2026. This follows the 10-Q filed today disclosing going concern doubt and a Nasdaq delisting hearing in late August. The commercial launch and revenue ramp are positive, but the delisting risk and FDA concerns about Ovaprene trial design remain key overhangs.
At the time of this announcement, DARE was trading at $1.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.5M. The 52-week trading range was $1.13 to $3.78. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.